MIRLET7I and ovarian carcinoma: Specifically in ovarian cancer, Let-7i upregulation decreased stemness and self-renewal, reduced anchorage-independent growth, decreased functional phenotypes associated with metastasis and increased sensitivity to PARPi and platinum-based therapies [59, 60].